WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:
- Lung, colorectal, breast, ovarian, prostate, pancreatic, and hematologic cancers
- Cancers prevalent in Asia (e.g., gastric cancer, hepatocellular carcinoma)
Specific areas of interest include:
- Targets and technologies that enable antibody and ADC approaches
- Oncogenic signaling mechanisms
- Tumor metabolism
- Epigenetics
- Directed tumor cell killing via immune-based mechanisms
- Precision medicine
- Peptide and bioconjugation technologies and analysis
- Functional genomics
Not actively seeking partnering opportunities in:
- Gene therapies
- Antisense / siRNA / shRNA therapeutics
- Systemic immune modulation
- Reformulated cytotoxic agents
- Radioconjugates
- Oncolytic Viruses
